BAC Drifts Lower While the Street Holds Its Ground

The positioning picture remains remarkably quiet for a stock moving in this direction. Short interest has continued its multi-week retreat, settling at 1.23% of free float — down 14.5% over the past month and the lowest level in the dataset. That builds on the sharp unwind flagged the prior two weeks, when roughly 11 million shares were covered in a single session. Borrow conditions confirm there is no squeeze dynamic at work: the cost to borrow has eased to 0.35% annualised, down 27% on the week, and availability is effectively unlimited at nearly 9,000% of short interest. The lending market is as loose as it gets. The ORTEX short score has drifted down slightly to 30.1, consistent with a stock that shorts have largely walked away from.

Options tell a similarly muted story. The put/call ratio is running at 1.27, fractionally below its 20-day average of 1.28, with a z-score of -0.24. That is neither defensive nor aggressive — it is the flattest options signal BAC has shown since April. The 52-week range on the PCR runs from 1.08 to 1.67, so the current reading sits in the middle, suggesting options traders are not taking a strong directional view into the next catalyst.

The Street remains firmly constructive, though recent analyst activity is now over a month old. Following Q1 earnings in mid-April, the overwhelming direction of analyst revisions was upward: multiple firms — including Jefferies, Keefe Bruyette, and Evercore ISI — raised targets while holding Buy or Outperform ratings, with targets clustering in the $59–$65 range. JPMorgan, the one notable exception, trimmed its target from $61.50 to $57.50 ahead of earnings in early April. The consensus still implies material upside, supported by the bull case: revenue up 7.2% year-over-year to $30.3 billion, net interest income growing 9%, and consumer banking net income rising 21%. The bear case centres on a softer CET1 ratio at 11.2% and the macro risk of a credit-quality deterioration that the current income statement does not yet reflect. Factor scores are constructive on earnings momentum — 90-day EPS momentum ranks in the 78th percentile — while the 95th-percentile dividend score underscores BAC's appeal to income-oriented holders. The dividend data in the snapshot is stale (last confirmed event in mid-2022), so current yield figures are omitted.

Insider activity is worth a brief mention, though the pattern is routine rather than alarming. CEO Brian Moynihan sold 18,083 shares on May 15 at $49.77 for approximately $900,000 — an award-and-sell transaction that mirrors identical trades in April and March, all at similar share counts, pointing to a scheduled plan rather than a discretionary decision. Chief Risk Officer Geoffrey Greener's sale of 126,756 shares at $53.00 on May 5 is a larger absolute figure, but it came at a higher price than where the stock sits today and carries a moderate significance score. Net insider flows over 90 days are marginally positive at roughly $56 million in value — not a signal in either direction.

The next scheduled catalyst is Q2 earnings, due July 14. Between now and then, the most telling variable is whether the price-to-target gap begins to close through stock price recovery or through target cuts — because the current configuration, where shorts are gone and analysts are bullish but the stock keeps softening, cannot persist indefinitely without one side adjusting.